Keywords: Acute lymphoblastic leukemia T – chemotherapy – MARALL 2006 protocol – Toxicity
Acute lyphoblastic leukemia represents a heterogeneous group of pathways clinical, biological, prognostic and therapeutic. The aim of this study was to evaluate the epidemiological, clinical, biological, prognostic and therapeutic aspects of patients treated and monitored by the MARALL 2006 protocol for acute lymphoblastic leukemia T at Center of Hematology and Oncology Paediatrics, Children’s hospital, Rabat, during the year 2013. In order to better understand this pathology in our context, a determination of the epidemiological, diagnostic as well as the therapeutic aspects of the patients included in this study was carried out. The average age is 6 years with extremes between 1.5 and 13 years, with a male predominance (Sex Ratio (M / F) is 1.43). The mean time of diagnosis is 22.9 days with extremes between 45 days and 7 days. The anemic syndrome was presented in all patients. Infectious syndrome was presented in 13 patients (92.8%), haemorrhagic syndrome was observed in 35.7% of patients with signs of epistaxis, purpura and bruising. A complete marrow insufficiency syndrome was found in 35% of the patients. The tumor syndrome is present in 92.8% of the patients, represented by Lymphadenopathy in nearly 64.2% of patients, hepatosplenomegaly is found in 71.4% of patients. All patients had abnormalities of the hemogram. More than half of the patients enrolled in the study had leukocytosis (64.2%), with 35.7% with a white cells greater than 50000 / mm³. All patients had more than 60% blastosis in the bone marrox aspirate. All patients were treated with the MARALL 2006 protocol.
Télécharger le memoire: Leucémie Aigue Lymphoblastique T (Dr. Brahim EL HASBAOUI)
Auteur : Dr Brahim EL HASBAOUI
Encadrant : Pr Maria EL KABABRI